BioSpace News Archive

Biotech Bay

Quark Pharmaceuticals, Inc. to Present Positive Phase II Efficacy and Safety Results of QPI-1002, A siRNA Targeting p53, for Prevention of Acute Kidney Injury Following Cardiac Surgery, at the EuroTIDES Conference

Quark Pharmaceuticals announced that positive results from a Phase 2 clinical study on its lead program QPI-1002 will be presented as an oral abstract at the EuroTIDES conference being held in Vienna Austria November 7-10, 2017.

November 7, 2017

·

3 min read

Drug Development

NanOlogy Announces First Patient Enrolled in a Phase II Clinical Trial of NanoPac for Treatment of Mucinous Cysts of the Pancreas

The Phase 2 dose-rising trial will evaluate the safety and preliminary efficacy of NanoPac delivered directly into MCNs by endoscopic ultrasound-guided fine needle injection.

November 7, 2017

·

4 min read

Drug Development

Boehringer Ingelheim’s Efficacy and Safety Maintained in Patients Who Switched From Humira to Biosimilar Cyltezo

The 48-week data showed that Cyltezo is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira in people with moderately-to-severely active RA, including in patients who switched from Humira to Cyltezo at week 24.

November 7, 2017

·

13 min read

Lianluo Smart Announces Strategic Investment in Guardion Health Sciences

Lianluo Smart today announced that the Company and related party Digital Grid together invested a total of $5M in GHS, a San Diego-based leader company focused on ocular health technologies and products.

November 7, 2017

·

3 min read

UCB Presents New Findings Advancing Patient Care for Chronic Inflammatory Diseases and Osteoporosis at 2017 ACR/ARHP Annual Meeting

Study findings suggest that opioids are vastly overprescribed as a treatment for pain associated with AS, often in lieu of more effective treatments such as anti-TNFs and NSAIDs.

November 7, 2017

·

22 min read

Business

Novus Therapeutics Announces the Promotion of Dr. Catherine Turkel to President

In this expanded role, Dr. Turkel will now be responsible global R&D as well as commercial strategy and development.

November 7, 2017

·

4 min read

Business

CTI BioPharma Reports Third Quarter 2017 Financial Results

In July 2017, the first patient was enrolled in PAC203, a Phase II clinical trial of pacritinib in patients with primary myelofibrosis who have failed prior ruxolitinib therapy.

November 7, 2017

·

16 min read

Policy

Ionis Announces Submission of NDA for Inotersen to the FDA

Inotersen is an antisense drug designed to reduce the production of transthyretin, or TTR, to treat patients with TTR amyloidosis, a severe, rare and fatal disease.

November 7, 2017

·

9 min read

Business

Nevro Reports Third Quarter 2017 Financial Results

Revenue for the three months ended September 30, 2017 was $82.3M versus $60.9M during the same period of the prior year, representing 35% growth as reported.

November 7, 2017

·

13 min read

Policy

FDA Performs Pre-Approval Inspection of Intersect ENT’s Menlo Park Facility

At the conclusion of the inspection, the FDA issued a Form 483 with four inspectional observations.

November 7, 2017

·

3 min read